ScreenerHero

MAIAMAIA Biotechnology Inc. Common Stock

AMEX · US · Healthcare · Biotechnology · maiabiotech.com
1.390USD0.00%Mkt Cap: 84.55M $P/E: —

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap84.55M $
Enterprise Value56.95M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.40M $
Revenue/Share—
Last Price1.390 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)1.25
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B22.42
EPS (TTM)-0.63
EPS (Forward)1.11
52W Range
0.870022% of range3.190
52W High3.190 USD
52W Low0.8700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-942.65%
ROA-230.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.84M $
CapEx (TTM)—
FCF Margin—
FCF Yield-16.31%
Net Debt-27.60M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio4.51
Quick Ratio4.41
Book Value/Sh0.0620 USD
Cash/Share0.4540 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.00 USD
Upside (mean)+763.3%
Target Range10.00 USD – 14.00 USD
$10.00+763.3% to mean$14.00
# Analysts2
Ownership
Shares Out.60.83M
Float55.61M
Insiders14.38%
Institutions22.23%
Short Interest
Short Ratio5.3d
Short % Float5.49%
Short % Out.5.04%
Shares Short3.06M
Short (prev mo.)3.41M
Technical
SMA 501.367 (+1.7%)
SMA 2001.466 (-5.2%)
Beta0.25
S&P 52W Chg19.18%
Avg Vol (30d)460.23K
Avg Vol (10d)284.93K
Technical Indicators
RSI (14)54.0
MACD0.0125
MACD Signal0.0060
MACD Hist.+0.0065
BB Upper1.482 USD
BB Middle1.337 USD
BB Lower1.192 USD
BB Width21.62%
ATR (14)0.0628 USD
Vol Ratio (20d)1.08x